Search

Label-free Immunoassay-Based Assessment for Chromate Exposure

Company: Lynntech, Inc. Agency/Program/Year/Phase: DOD / SBIR / 2014 / 2
Abstract: … most widely used industrial metals. Several million workers worldwide are estimated to be exposed to chromium compounds in a variety of industries, including electroplating, welding, and chromate painting. Hexavalent chromium (a.k.a., chromate or Cr(VI)) via inhalation… more

A Human Fc Bifunctional Fusion Protein to Treat Severe Allergic Asthma

Company: TUNITAS THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: … of the human gamma1 Fc linked to portions of the human epsilon Fc chain, has unique mechanistic properties that should translate to a next-generation therapeutic option for patients with severe allergic asthma and food allergy. Effective treatments for severe inhalant… more

Nicotine delivery to rodent with lung alveolar region-targeted aerosol technology

Company: AFASCI, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: … was in response to NIH PA11-096, PHS 2011-02 'Omnibus solicitation for SBIR/STTR Grant Application' under NIDA 2, Development of Alternate Drug Delivery Dosage Forms for Drugs Abuse Studies. We have developed an alveolar region-targeted aerosol/inhalation… more

Evaluation of a new class of molecules for treating MRSA infective endocarditis

Company: ARADIGM CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: … orally or by IV. Unfortunately, these therapies often fail. Thus, there is a need to develop new anti-mycobacterial therapies for both diseases. The overall objective of this project is test the efficacy of two new formulations of ciprofloxacin (Ciprofloxacin for Inhalation,… more

Rapidly boosting innate immunity in the lungs to protect against pneumonia

Company: PULMOTECT, INC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: … of treatments in an effort to prevent pneumonia. Despite this expenditure, pneumonia continues to occur in 15-20% of acute leukemia patients. Pulmotect's Solution: Pulmotect has identified and is developing a novel, proprietary technology to address the risks of … more

Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF

Company: SAVARA INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: … a faster decline of lung function and a 6 years shorter median life-expectancy compared to CF patients without MRSA. Unfortunately, there is no effective and safe treatment of persistent MRSA infections available for CF patients. Savara Inc. is developing a novel inhaled… more

Compact, Lightweight Dynamic Saturation Cloud Condensation Nuclei Spectrometer for UAV Missions

Company: Hal Technology, LLC Agency/Program/Year/Phase: DOE / SBIR / 2013 / 1
Abstract: … microphysics and radiative properties of ambient aerosols, the developed spectrometers will advance the existing commercial condensation nuclei counter markets for both industrial and commercial applications. Of primary concern in the working environment are inhalation … more

A therapeutic Fc gamma Fel d1 chimeric protein vaccine to treat cat allergy

Company: TUNITAS THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 2
Abstract: … for cat allergy as not only an important new therapeutic for catallergy/asthma but also as the sign post for development of this approach for the treatment of severe IgE mediated food allergy. PUBLIC HEALTH RELEVANCE: Effective treatments to for severe inhalant allergy… more

Therapeutic peanut allergen Fc gamma chimeric proteins to treat peanut allergy

Company: TUNITAS THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / STTR / 2012 / 2
Abstract: …e key food antigens will be relatively straightforward. PUBLIC HEALTH RELEVANCE: Therapeutic peanut allergen-Fc-gamma chimeric proteins to treat food allergy Effective treatments to for severe allergic food allergy represent a major unmet medical need. As opposed to … more

Rapid Detection of Mycotoxins

Company: Lynntech, Inc. Agency/Program/Year/Phase: USDA / SBIR / 2012 / 1
Abstract: … are extremely hazardous to humans. Exposure to even nano gram quantities of trichothecene mycotoxins, such as T-2 toxin, can cause severe reactions. Central nervous systems injury, as well as gastrointestinal and hematological toxicity can occur from ingestion or … more

Low cost ammonia sensor for agricultural emissions

Company: Mesa Photonics, LLC Agency/Program/Year/Phase: USDA / SBIR / 2012 / 1
Abstract: … is emitted from agriculture can create health problems for workers and, surprisingly, for people far from the agricultural operation. Once released into the air, the ammonia undergoes a series of chemical reactions that lead to small particles (known as PM2.5) that are inhaled… more

Improving Chemotherapy with a Novel Oxygen-Delivery Protein

Company: OMNIOX, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: … to correlate with poorer patient outcomes inmultiple cancer types. Oxygenating hypoxic regions of tumors has the potential to, sensitizing tumors to antineoplastic therapies. Previous efforts to eliminate tumor hypoxia via hyperbaric oxygen, blood transfusions, or inhaled… more

Thermostable Measles-Rublella Vaccines for Respiratory Delivery

Company: Universal Stabilization Technologies, Inc. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 2
Abstract: …, stable powders have been produced in high yield that can be stored at least 10 months at 37°C. The specific aims of this project are: 1) Develop a formulation for stable measles-rubella vaccine powder utilizing the PBV process 2) Micronize product to an inhalable particle… more

Preventing asthma exacerbations by reducing viral respiratory infections

Company: PULMOTECT, INC Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: … developing novel therapeutics that stimulate the innate immune system to protect against infectious diseases, even in cases of severely compromised immunity. Proof-of-concept data has shown that this technology effectively protects against a broad range of inhaled pathogens.… more

Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF

Company: SAVARA INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): Savara Inc. is developing a novel inhaled dry-powder form of vancomycin (AEROVANC) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection, initially in cystic fibrosis (CF) patients and subsequently in other high… more

Targeting surface-bound IgE as a novel allergy therapeutic

Company: SIXAL CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: …c health issue and particularly so in developed countries such as the US. Novel effective treatment options for allergies remain a major unmet need; no effective therapy is available for severe food allergies such as peanut allergy and no new platforms for inhalant allergy have… more

Development of human thioredoxin as a mucolytic therapy for Cystic Fibrosis

Company: ORPRO THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: … and infection. In the case of CF, an autosomal recessive disease affectingapproximately 30,000 patients in the US and 70,000 world-wide, current therapies designed to increase the fluidity of mucus and facilitate clearance involve the use of hypertonic saline inhalation to… more

A Human Fc Bifunctional Fusion Protein to Treat Severe Allergic Asthma

Company: TUNITAS THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: …eutic molecule is a genetically engineered human fusion protein consisting of a portion of the human gamma1 Fc linked to a portion of the human epsilon Fc chain [(hinge-h2-3(1)-linker- (ch2-3-4()] that is designated as GE2 . Effective treatments for severe inhalant… more

Prevention of Allergic Rhinitis with Topical Immunomodulating Antibodies

Company: RADIX THERAPEUTICS, LLC Agency/Program/Year/Phase: HHS / STTR / 2011 / 1
Abstract: …nting or substantially reducing the allergic response to subsequent nasal exposure of mountain cedar pollen. Positive Phase I results will provide proof of concept that nasal instillation of optimized antibodies can provide an effective barrier between an inhaled allergen… more

Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis

Company: GLYCOMIRA, LLC Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: … diseases, and pregnancy complications. Periodontal disease is exacerbated in diabetics and smokers due to increased exposure to advanced glycation end-products (AGEs), which arise from spontaneous glycation of proteins.AGEs from high blood sugar or from inhalation of AGES… more

Broncho-adventitial Drug Delivery: Paclitaxel for Bronchial Carcinoma

Company: MERCATOR MEDSYSTEMS, INC. Agency/Program/Year/Phase: HHS / STTR / 2011 / 2
Abstract: …(b) statistically showing a non-toxic dose of a common chemotherapeutic, anti-proliferativedrug like paclitaxel can have broad-ranging clinical impact, (c) bronchial adventitial therapy may be more effective in the prevention and treatment of bronchial maladies than inhalation… more

Multifunctional Antisense Therapeutics Nanocarrier and Inhalation Device

Company: Physical Optics Corporation Agency/Program/Year/Phase: DOD / SBIR / 2011 / 2
Abstract: To address the CBD need for improved formulations to enhance the ease of use and bioavailability of antisense therapeutics, Physical Optics Corporation (POC) proposes to advance development of a Multifunctional Antisense Therapeutics Nanocarrier and Inhalation Device (MATEN).… more

Rapidly boosting innate immunity in the lungs to protect against pneumonia

Company: PULMOTECT, INC Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: … an estimated 44,700 leukemia patients spend more than one-half billion dollars on a range of treatments in an effort to prevent pneumonia. Pulmotect's Solution: Pulmotect has identified and is developing a novel technology to address the risks of inhaled microbes.… more

A High Efficiency Corticosteroid Dry Powder Inhaler for Pediatric Use

Company: SAVARA INC. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: DESCRIPTION (provided by applicant): Asthma is a chronic respiratory disease with a global human and economic burden on patients, and society. Asthma treatment mainly consists of inhaled corticosteroids and bronchodilators, which enable adult populations to function well despite… more

Development of a Field-Deployable Device to Rapidly Measure Blood Cyanide Levels

Company: DIAGNOSTIC CONSULTING NETWORK, INC. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: … test. If successful, this test will provide the medical community and first responders with a fast, reliable and economic alternative to determine cyanide poisoning. PUBLIC HEALTH RELEVANCE: Cyanide poisoning hasbeen recognized as a threat from smoke inhalation and… more